A detailed history of Sherbrooke Park Advisers LLC transactions in Fate Therapeutics Inc stock. As of the latest transaction made, Sherbrooke Park Advisers LLC holds 138,339 shares of FATE stock, worth $229,642. This represents 0.11% of its overall portfolio holdings.

Number of Shares
138,339
Previous 28,652 382.82%
Holding current value
$229,642
Previous $94 Million 415.21%
% of portfolio
0.11%
Previous 0.02%

Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$3.12 - $5.57 $342,223 - $610,956
109,687 Added 382.82%
138,339 $484 Million
Q2 2024

Aug 14, 2024

BUY
$3.26 - $7.08 $93,405 - $202,856
28,652 New
28,652 $94 Million

Others Institutions Holding FATE

About FATE THERAPEUTICS INC


  • Ticker FATE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 97,000,304
  • Market Cap $161M
  • Description
  • Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell...
More about FATE
Track This Portfolio

Track Sherbrooke Park Advisers LLC Portfolio

Follow Sherbrooke Park Advisers LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Sherbrooke Park Advisers LLC, based on Form 13F filings with the SEC.

News

Stay updated on Sherbrooke Park Advisers LLC with notifications on news.